Skip to main content

Table 7 Active Phase III clinical trials with novel therapeutic drugs in mRCC

From: Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

NCT name

Drug/procedure combinations

Primary outcome

NCT03055013

PROSPER

Nephrectomy vs. Perioperative Nivolumab

RFS

NCT03592472

RENAVIV

Pazopanib + Placebo vs. Pazopanib + Abexinostat

PFS

NCT03260894

Sunitinib/Pazopanib vs. Pembrolizumab + Epacadostat

ORR

NCT03288532

RAMPART

Durvalumab vs Durvalumab + Tremelimumab

DFS

NCT03142334

Pembrolizumab (Adjuvant setting)

DFS

NCT03138512

CheckMate 914

Nivolumab + Ipilimumab (Adjuvant setting)

DFS

NCT03091192

Savolotinib vs. Sunitinib

PFS

NCT03024996

IMmotion 010

Atezolizumab (Adjuvant setting)

DFS